Rachel Freedman, MD

Medical Oncology

Rachel Freedman, MD

View full profile

Related Videos

Rachel Freedman, MD discusses phase 2 ATOP study Video

Rachel Freedman, MD discusses phase 2 ATOP study

Dana-Farber Cancer Institute's Rachel Freedman, MD, presents results from the phase 2 ATOP study showing older patients with HER2+ breast cancer receiving adjuvant T-DM1 had a favorable 5-year survival with manageable toxicity. ATOP is ...